Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBS 10

Drug Profile

NBS 10

Alternative Names: AMR-001; CLBS 10; NBS10

Latest Information Update: 28 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorcyte
  • Developer Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Brain injuries
  • Discontinued Myocardial infarction

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
  • 15 Mar 2016 Caladrius out-licenses CD34 ischemic repair technnology to SPS Cardio LLC
  • 18 Dec 2015 NBS 10 is available for licensing as of 18 Dec 2015. http://www.caladrius.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top